Anzeige
Mehr »
Lynx Broker
Login
Donnerstag, 22.08.2019 Börsentäglich über 12.000 News von 607 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Zur alten Webversion

WKN: 853260 ISIN: US4781601046 Ticker-Symbol: JNJ 
Tradegate
22.08.19
15:56 Uhr
118,58 Euro
-0,08
-0,07 %
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
118,40
118,48
16:15
118,38
118,48
16:15

Aktuelle News zur JOHNSON & JOHNSON Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
JOHNSON & JOHNSON Aktien jetzt im kostenlosen Demokonto handeln!
15:35Get as much Spravato as you can, Trump orders VA while suggesting J&J should offer it to veterans for free-
15:22Johnson & Johnson opioid trial judge expected to issue landmark verdict Monday2
13:46J&J's Darzalex OK'd in Japan for first-line multiple myeloma2
07:42Major J&J Opioid Ruling Expected Monday Out of Oklahoma9
MiOklahoma judge to rule on Monday in opioid lawsuit against J&J6
MiJ&J to hear judgement in OK opioid case Monday2
MiJohnson & Johnson Stock Is a Gamble, but an Interesting One9
Di3 Healthcare Stocks to Trade: UNH, JNJ and PFE15
DiPharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY8
15.08.Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study6
14.08.Eli Lilly's Taltz beats J&J's Tremfya in psoriasis head-to-head - but the marketing brawl is just beginning6
14.08.JNJ Stock Is a Way Better Investment Than Bonds or CDs17
14.08.Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial3
13.08.Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study2
13.08.Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt2
13.08.Lilly's Taltz beats J&J's Tremfya in post-market psoriasis study1
12.08.FDA OKs use of J&J's Situro for younger TB patients2
09.08.Johnson & Johnson Is A Huge Pharma Stock - But Should You Buy It?52
08.08.Not Withholding Interim Compensation From Patients Who Want More, Johnson & Johnson Tells Court5
08.08.J&J faulty hip implant case: Delhi HC to decide on quantum of compensation4
Seite:  Weiter >>
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
50,3,25